Business Context and Reporting Period
This Form 8-K is filed by ADVENTRX Pharmaceuticals, Inc. (not Savara Inc.) on August 8, 2011. The report serves to announce the company's financial results for the three and six months ended June 30, 2011, as detailed in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the referenced press release (Exhibit 99.1) but are not included in the body of this 8-K document.
Material Changes
No material changes or comparative financial data are disclosed within this specific filing text. The document solely references the issuance of the press release containing the results.
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, risk factors, or details on contingencies. It explicitly states that the information in Item 2.02 and Exhibit 99.1 is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934 and is not to be incorporated by reference into other filings.
Investor Verification Checklist
- Verify the actual financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (the press release dated August 8, 2011), as they are absent from this summary document.
- Confirm the registrant name is ADVENTRX Pharmaceuticals, Inc., noting the discrepancy with the "Savara Inc." metadata provided in the request.
- Check the company's cash runway and burn rate in the full press release, as this is a critical metric for a pharmaceutical company not detailed here.